
Caitlin Cox
News Editor at TCTMD
News Editor @TCTMD | Associate Director, Editorial Content @CRFheart | Knitter & Nerd | Winner of the 2020 @NIHCMfoundation Trade Journalism Award | She/Her
Articles
-
4 days ago |
tctmd.com | Caitlin Cox
The observational data can’t capture details like the timing, amount, and type of exposure. Still, there’s a “safety signal.” Cannabis use does in fact raise the risk of major adverse cardiovascular events—acute coronary syndromes, stroke, and CV death—a new meta-analysis confirms, though many specifics related to the type and amount of exposure are still elusive.
-
1 week ago |
tctmd.com | Caitlin Cox
Most cases are subclinical, but given the newness of the therapy, it’s necessary to keep tabs on the issue going forward. Approximately one in nine patients develop leaflet thrombosis in the first 10 months after transcatheter tricuspid valve replacement (TTVR), according to a meta-analysis. Most cases are subclinical, but researchers say they may yet be tied to future problems, so it’s important to keep tabs on the complication as the treatment’s use expands. Led by Mark J.
-
2 weeks ago |
tctmd.com | Caitlin Cox
Alcohol is a hot topic—the new statement sums up the evidence and provides ways to help patients understand the risks. Much is still unknown about whether—if at all—alcohol consumption fits into a lifestyle that promotes cardiovascular health, according to a new scientific statement from the American Heart Association. Mariann R.
-
2 weeks ago |
tctmd.com | Caitlin Cox
The GLUCOSE model recommends insulin doses that are tailored to each patient’s blood-sugar fluctuations. For patients recovering after cardiac surgery, a new algorithm based on artificial intelligence (AI) could streamline the process of tracking shifts in glucose and adjusting insulin accordingly, researchers say. The reinforcement-learning model, known as GLUCOSE, is designed to recommend insulin doses tailored to each patient’s needs with the hope of avoiding unnecessary complications.
-
2 weeks ago |
tctmd.com | Caitlin Cox
The advent of ATTR-specific drugs, though pricey, is enabling better survival in these overlapping diseases, researchers say. With targeted treatment using both medical therapy for transthyretin-associated cardiac amyloidosis (ATTR-CA) and valve replacement for aortic stenosis (AS), patients with the dual pathology can fare quite well, according to registry data from the AS-Amyloidosis Consortium.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →X (formerly Twitter)
- Followers
- 1K
- Tweets
- 4K
- DMs Open
- No

RT @UKheartresearch: Pressure-Based Physiological Testing Results Diverge Between LAD, LCx https://t.co/PZ810lXRRp @DrOzanDemir @divaka_pe…

RT @DrOzanDemir: 📰https://t.co/clZ1sN1lCi 🔗https://t.co/ngU7Px21yb ⁉️ Should diagnostic thresholds for FFR, iFR, CFR be specific to each…

RT @TCTMD_Yael: A new @TCTMD Heart Sounds episode is live! If you'd like @michaelTCTMD @TCTMD_Caitlin @lamckeown1 @ToddNeale and me to keep…